Share:
LUND, Sweden, May 5, 2021 /PRNewswire/
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that preclinical data on its agonist anti-CD40 antibody mitazalimab has been published in the scientific journal Cancer Immunology, Immunotherapy.
The published data show that mitazalimab activates dendritic cells and tumor-reactive T cells resulting in enhanced anti-tumor efficacy in combination with a model cancer vaccine.
Title: The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells and enhances anti-tumor efficacy of a model cancer vaccine in vivo
Journal: Cancer Immunology, Immunotherapy
Authors: Adnan Deronic et al. A publication in a prominent peer-reviewed journal such as Cancer Immunology, Immunotherapy is very encouraging and validates our findings. These data further highlight the strong potential for mitazalimab to be combined with other therapie
Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field
LUND, Sweden, May 4, 2021 /PRNewswire/ Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research agreement with BioArctic AB, a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer s disease and Parkinson s disease. Under the agreement, Alligator will employ its proprietary antibody generation technologies in collaboration with BioArctic to develop new product candidates. We are very pleased that BioArctic has recognized the power of Alligator s proprietary phage display libraries which have been successfully used to generate Alligator s suite of immuno-oncology programs. The application of this technology to the neurodegenerative field demonstrates the broad applicability of our powerful platform, said Malin Carlsson,
Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
High activity during the first quarter So far, 2021 has been characterized by high activity, with a research collaboration that validates our Discovery concept, and good progress of our clinical programs, with ATOR-1017 and mitazalimab entering clinical efficacy studies this year.
Malin Carlsson, Interim CEO Alligator Bioscience AB
SIGNIFICANT EVENTS JANUARY-MARCH
Pipeline:
New preclinical data were released in an abstract for a poster presentation at the AACR Annual Meeting 2021, demonstrating that mitazalimab synergizes with chemotherapy.
Company:
Søren Bregenholt was appointed as new CEO to strengthen Alligator s business development activities and clinical progress on an international level.
Oversubscribed rights issue generated proceeds of SEK 86 milli
Alligator Bioscience AB: Interim report January-March 2021 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.